SINAI ANTIBIOTIC SELECTION GUIDE
DISCLAIMER: Clinical recommendations in this guide are offered as general empiric therapy based on nationally accepted guidelines and adjusted according to Sinai antibiogram. Clinical judgement and cultures results / susceptibilities should always guide the physician in the selection, dosing, and duration of antimicrobial therapy individual patients. All antimicrobial dosing is for patients with normal renal and hepatic function. Please use the Sinai nomogram for vancomycin dosing. All aminoglycosides will be dosed by the TDM consult service.
EMPIRIC ANTIBIOTICS DURATION OF PATHOGENS Bacterial Meningitis
If age >50 / alcoholism / immunocompromised, ADD:
Chloramphenicol 12.5mg/kg IV Q6h (max 4g/day) PLUS Bactrim
Neutropenic
Zosyn® 3.375gm IV Q4h PLUS Aminoglycoside (gentamicin /
** Vancomycin (consider adding if mucositis, skin / catheter site
infection, history of MRSA colonization OR clinical deterioration /
persistent fever despite empiric antibiotics after 1-2 days)
** If persistent fever after 5 days, add Caspofungin 70mg IV x 1, then 50mg IV Qday
Ceftriaxone 1gm IV Q24h PLUS Azithromycin 500mg Q24h or
Unasyn® 3gm IV Q6h PLUS Azithromycin 500mg Q24h
Ceftriaxone 2gm IV Q24h or Unasyn® 3gm IV Q6h
PLUS Moxifloxacin 400mg Q24h or Azithromycin 500mg Q24h
PCN allergy – Moxifloxacin PLUS Aztreonam 2gm IV Q8h
Zosyn® 3.375gm IV Q4h or Cefepime 2gm IV Q12h PLUS Aminoglycoside (gentamicin / tobramycin) PLUS Moxifloxacin 400mg Q24h PCN allergy – substitute Aztreonam 2gm IV Q8h for Zosyn® or Cefepime
If suspecting community-acquired MRSA necrotizing pneumonia:
Consider Clindamycin 900mg IV Q8h or Linezolid 600mg Q12h
Early onset (<48 hours) / No known risk factors for MDRP:
Moxifloxacin 400mg Q24h or Ceftriaxone 2gm IV Q24h or Unasyn®
Acinetobacter spp. Late onset (>48 hours) / Risk factors for MDRP:
Zosyn® 3.375gm IV Q4h or Cefepime 2gm Q8h or Imipenem 1gm
GPC = gram-positive cocci; GNC = gram-negative cocci; GPB = gram-positive bacilli; GNB = gram-negative bacilli; ESBL = Extended-Spectrum -Lactamases; MDRP = Multi-drug Resistant Pathogens
Cellulitis
Cefazolin 1gm IV Q8h or Nafcillin 1gm IV Q4h
Oral therapy – Cephalexin 500mg QID or Dicloxacillin 500mg QID
PCN allergy / suspecting community-acquired MRSA:
Clindamycin 600mg IV Q8h or 300mg PO QID
Bactrim 2.5mg/kg IV Q8h or DS 2 tabs PO BID + Rifampin 300mg
If facial cellulitis or signs / sx of sepsis present:
Diabetic Foot
**No antibiotics for clinically uninfected ulcerations**
Infections
Unasyn® 3gm IV Q6h / Augmentin® 875mg PO TID
PLUS Bactrim 2.5mg/kg IV Q8h / Bactrim DS 2 PO BID
Clindamycin 600mg IV Q8h / Clindamycin 300mg PO QID PLUS
Ciprofloxacin 400mg IV Q8h / 750mg PO BID
Zosyn® 3.375gm IV Q6h PLUS vancomycin PCN allergy – aztreonam 1-2gm IV Q8h PLUS Metronidazole 500mg Q8h PLUS vancomycin
Abdominal
Cefazolin 1-2gm IV Q8h + Metronidazole 500mg Q8h
Ciprofloxacin 400mg IV Q12h + Metronidazole 500mg Q8h
Zosyn® 3.375gm IV Q6h Aminoglycoside + Metronidazole 500mg Q8h Aztreonam 1-2gm Q8h + Metronidazole 500mg Q8h
Clostridium difficile –
Mild – moderate disease: metronidazole 500mg IV/PO Q8h
Associated Diarrhea
First relapse: Repeat treatment as in initial episode above
Second relapse: Tapering and pulsed oral vancomycin:
Vancomycin 125mg PO QID x 14 days, followed by rifaximin 400mg PO BID x 14 days
Cefazolin 1gm IV Q8h or cephalexin 500mg PO QID
** If GPC in pairs/chains seen on gram stain, consider adding ampicillin
GPC = gram-positive cocci; GNC = gram-negative cocci; GPB = gram-positive bacilli; GNB = gram-negative bacilli; ESBL = Extended-Spectrum -Lactamases; MDRP = Multi-drug Resistant Pathogens
RINGWORM WHAT IS IT? "Ringworm" is the common name for the skin infection caused by a special group of fungi; it is not caused by a worm at all. The fungi feed upon the dead cells of skin and hair causing, in people, a classic round, red lesion with a ri ng of scale around the edges and normal recovering skin in the center. Because the ring of irritated, itchy skin looked like a
For Immediate Release Genzyme Reports Financial Results for the First Quarter of 2010 -------------------------- Provides Update on Product Supply and Consent Decree Terms CAMBRIDGE, Mass. – Genzyme Corp. (NASDAQ: GENZ) today reported that first-quarter revenue was $1.07 billion, compared with $1.15 billion in the same period last year, reflecting limited shipments of Cer